BrosMed Announces CE Mark and Launch for Apollo™ Balloon Dilatation Catheter
Release time:
2014-02-25
February 25, 2014— Following the CE approval and launch Artimes™ Balloon Dilatation Catheter, BrosMed announced CE Mark and Launch of its Apollo™ Balloon Dilatation Catheter which is now approved in the EU for the interventional cardiovascular use.
February 25, 2014— Following the CE approval and launch Artimes™ Balloon Dilatation Catheter, BrosMed announced CE Mark and Launch of its Apollo™ Balloon Dilatation Catheter which is now approved in the EU for the interventional cardiovascular use. Apollo™ rapid exchange PTCA balloon catheter is intended to be used for percutaneous transluminal coronary angioplasty (PTCA) for the purpose of improving myocardial blood flow in the localized stenotic lesion of the coronary arteries.
“The CE approval of Apollo™ balloon dilatation catheter will definitely enhance our balloon product portfolio and today we are excited having both Artimes™ semi-compliant and Apollo™ high pressure non-compliant catheters available with CE approvals. I believed that the Apollo™ will be workhorse balloon for the post-dilatation cases while Artimes™ will be ideal weapon dealing most complex cases including Chronic Total Occlusion (CTO)” said by Thomas Dong, VP of Technology & Strategy.
“We obtained lots of affirmative feedbacks from key opinion leader (KOL) after launching Artimes™, it should the same success to Apollo™ once it is available in the market”, added by Stephen Lee, VP of Operation & Regulatory Affairs.
Join with Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announced CE MDR Approval of New Generation Conger™ Plus Hydrophilic Guidewires
Designed for superior crossability and maneuverability in peripheral interventions, Conger Plus now offers 116 models with expanded sizes (OD 0.018'' to 0.038'') and lengths (up to 300cm).
2025-04-25
Meet BrosMed at ESC Congress 2024
BrosMed Medical is delighted to participate in the ESC Congress 2024 from August 30th to September 2nd in London, UK.
2024-08-15
BrosMed Medical Announces Scott J. Addonizio as Chief Operating Officer
2024 August 1st – BrosMed Medical is pleased to announce the appointment of Scott J. Addonizio as its Chief Operating Officer (COO), effective immediately. Mr. Scott J. Addonizio brings a wealth of experience and expertise to BrosMed, with a distinguished career spanning almost 30 years in the medical device industry. Prior to joining BrosMed, Mr. Addonizio served as SVP at Cordis and COO at MedAlliance Swiss Medical Technology.
2024-08-01
CTO&CHIP PCI – Insights from the clinical practice (Ⅱ)
July 30, 2024 @16:00-17:30 (Beijing Time) Join BrosMed Medical on Tuesday, July 30 for an enlightening discussion that unites cardiologists from Malaysia, China, India, Tunisia and Portugal, where clinical expertise harmoniously fuses with CTO&CHIP innovation. At this exclusive webinar, we’re orchestrating a confluence of valuable insights, drawing from the collective wisdom of seasoned interventional cardiologists.
2024-07-26
BrosMed Announced CE MDR Approval of New Generation PTA SC Balloon Dilatation Catheters
May 27, 2024- BrosMed announced that it receives European Medical Device Regulation (MDR) certification for the New Generation PTA SC Balloon Dilatation Catheters (Brand Name: Polux™ Pro 014, Minerva™ Pro 018 and Atropos™ Pro 035).
2024-05-27